A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

The best way to fight cancer is to detect and start treatment early. Dr Atangwho shares signs to watch out for prostate ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

AngioDynamics has reported two-year data from the PRESERVE pivotal trial, showing durable outcomes for the NanoKnife IRE system in treating intermediate-risk prostate cancer.

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

BALTIMORE, May 12, 2026 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2026 amendment to the Advanced ...

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

A new urine test performed better than PSA-based testing and MRI for monitoring low-risk prostate cancers on active ...

Men whose fathers diagnosed with prostate cancer at an early age faced a fourfold higher risk for early-onset prostate cancer, with a particularly elevated risk for high Gleason score disease. Also, ...

A breakthrough study has identified the genetic risk factors that contribute to increased prostate cancer in African men. The study, the largest of its kind, recruited 7,500 men from eastern, southern ...